Alert: Alcon voluntarily recalls Systane Ultra PF lot due to potential fungal contamination
This action follows a consumer complaint of foreign material in a sealed single-use vial.
Related Articles
Eyecare wrapped: Top stories from Modern Retina in 2024
Look back on some of the top stories on Modern Retina from 2024 as we gear up for an incredible 2025.
Childhood Visual Impairment Could Increase the Odds of Developing Adult Dementia
People who had visual impairment in childhood appear to be at greater risk for developing dementia after age 65, according to a recent study.
Galimedix Therapeutics initiates eDREAM phase 2 clinical trial in dry age-related macular degeneration
The trial is evaluating GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.
Glaucoma Awareness Month | National Eye Institute
January is Glaucoma Awareness Month. View resources from the National Eye Health Education Program to help you encourage people to get checked for glaucoma.
DR/DME Cases & Clinical Conversations – Part 2
This activity, featuring retina specialists from Cole Eye Institute, will mimic the format of traditional grand rounds. Drs. Abraham, Antaki, Nithianandan, and Tayeb will present…
Glaucoma Basics & FAQs
Learn about Glaucoma, Glaucoma signs and symptoms, and how to prevent blindness from Gluacoma
Reviews Supplements RP-Year in Review
Wills Eye Resident Series : A patient presents with decreased vision after an injury , p. 62 medicare Q & A 2024 Reimbursement Update Wills…
RESTORE study highlights persistent vision recovery in LHON patients with MT-ND4 mutation
The multinational, multicenter, prospective RESTORE Study is the 5-year follow-up study of the phase 3 clinical RESCUE and REVERSE Studies of lenadogene nolparvovec to treat…
Retinal Annular Ring Lines of White Without Pressure
This case report discusses a diagnosis of white without pressure in the peripheral retina of a patient with high myopia.
European Medicines Agency to assess semaglutide for link to NAION
The Danish Medicines Agency requested the EMA’s Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition.